Autopsy report · NCT03658213

To Compare ZOLADEX 10.8 mg With ZOLADEX 3.6mg in Chinese Pre-menopausal ER+ HER2- Early Breast Cancer.

Cause of deathOther Automatic label, confidence 0.5, unverified. How labels are made.

“CTP of LARES has been out of the expire date, we are trying RWS pathway for the indication expend”

The sponsor’s own words in the registry.

Life of this trial

Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status: Withdrawn
Phase: Phase 3
Sponsor: AstraZeneca
Sponsor type: Industry
Conditions: Breast Cancer
Interventions: ZOLADEX 10.8 mg; ZOLADEX 3.6mg
Participants: 0
Sites: 11
Countries: China

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.